A PYMNTS Company

Glenmark Pharmaceuticals Subsidiary Reaches $37.75 Million Settlement in US Antitrust Case

By  |  August 6, 2025

Glenmark Pharmaceuticals Ltd announced Wednesday that its U.S.-based subsidiary, Glenmark Pharmaceuticals Inc., USA, has agreed to pay $37.75 million to resolve antitrust litigation concerning alleged misconduct in the generic drug market. The agreement pertains to consolidated lawsuits in the Eastern District of Pennsylvania involving claims of price-fixing, market allocation, and broader anticompetitive behavior, according to CNBC.

    Get the Full Story

    Complete the form to unlock this article and enjoy unlimited free access to all PYMNTS content — no additional logins required.

    yesSubscribe to our daily newsletter, PYMNTS Today.

    By completing this form, you agree to receive marketing communications from PYMNTS and to the sharing of your information with our sponsor, if applicable, in accordance with our Privacy Policy and Terms and Conditions.

    The proposed settlement is with the putative direct purchaser class and still awaits court approval. If approved, Glenmark USA will make two payments: $11.1 million following preliminary approval and the remaining $26.65 million by April 1, 2026. As per CNBC, this litigation forms part of a wider legal battle in which Glenmark USA is a named defendant in multiple class action and direct-action suits brought by various stakeholders including direct purchasers, end-payers, and private entities. These suits allege both individual and industry-wide conspiracies to manipulate prices and restrict competition in the generic drug sector.

    Despite agreeing to the financial settlement, Glenmark has firmly denied any wrongdoing. The company emphasized that the resolution does not represent an admission of liability but is intended to eliminate prolonged litigation and uncertainty.

    Related: US Judge Approves $70M Settlement in Merck and Glenmark Antitrust Case

    This development comes on the heels of additional regulatory scrutiny for Glenmark. Just last month, the U.S. Food and Drug Administration (USFDA) issued a Warning Letter to the company following an inspection of its manufacturing site in Pithampur, India, conducted between February 3 and 14, 2025. The agency cited multiple violations of Current Good Manufacturing Practice (CGMP) regulations.

    According to the FDA’s letter, Glenmark’s investigations into product issues—particularly dissolution failures in potassium chloride extended-release capsules and another unnamed product—were insufficient and lacked sound scientific rationale. The regulator also noted significant delays in conducting stability tests, which in turn led to postponed product recalls and delayed issuance of field alerts.

    Source: CNBC